PATHOGENESIS OF AUTOIMMUNE THROMBOCYTOPENIA

Information

  • Research Project
  • 6041047
  • ApplicationId
    6041047
  • Core Project Number
    R01HL061846
  • Full Project Number
    3R01HL061846-01S1
  • Serial Number
    61846
  • FOA Number
    RFA-HL-98-01
  • Sub Project Id
  • Project Start Date
    9/30/1998 - 27 years ago
  • Project End Date
    8/31/2003 - 22 years ago
  • Program Officer Name
  • Budget Start Date
    4/15/1999 - 26 years ago
  • Budget End Date
    8/31/1999 - 26 years ago
  • Fiscal Year
    1999
  • Support Year
    1
  • Suffix
    S1
  • Award Notice Date
    4/12/1999 - 26 years ago

PATHOGENESIS OF AUTOIMMUNE THROMBOCYTOPENIA

DESCRIPTION (Adapted from applicant's abstract) Idiopathic Thrombocytopenia (ITP) is an autoimmune disorder characterized by production of antiplatelet antibodies and consequent immune-mediated platelet destruction. The initial stimulus for the autoantibody response in ITP is not known, even though it is one of the most common autoimmune diseases affecting both adults and children. ITP may occur as an isolated phenomenon or in association with many conditions, for example: acquired or congenital immune dysregulation, pregnancy, viral infection like HIV or EBV, or systemic lupus erythematosus (SLE). The dominance of antiplatelet autoantibodies in such a wide variety of immune diseases suggests that there may be an alternative mechanisms to antiplatelet production as compared to other autoimmune diseases. In this grant, the applicants present a model for ITP and hypothesize that the platelet itself may act to short circuit the process of antigen specific immunoglobulin production allowing the emergence of autoantibodies which are normally restricted by a network of anti-idiotypic T and B cell clones. Ordinarily, somatic mutation and antigen selection in the B lymphocyte proceed under the strict supervision and symmetrical evolution of idiotype specific T cell clones. In their model, the platelet, mimicking a T cell, could promote polyclonal expansion of previously restricted clones without the concomitant involvement of regulatory T cells or macrophages. To test this hypothesis, the applicants will focus their efforts in following areas: SPECIFIC AIM #1: To determine the effect of ligation of CD40, membrane lg (mig) receptor, and FcRyIII on IL-1alpha and IL-1beta gene expression and production in B cells and dendritic cell/macrophages. SPECIFIC AIM #2: To determine the effect of polyclonal expansion and epitope shifts, they will use limited oligonucleotide substitutions (within the immunoglobin framework or CDR3 region) to measure changes in antigen binding using a uniquely engineered baculovirus protein expression system. Their long term goal is to identify the dysregulation which drives the production of platelet autoantibody. They believe that interruption of this process will return the immune system to a more restricted process of B cell immunoglobulin production allowing T cell regulation to further limit the emergence of autoreactive clones. (End of Abstract)

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R01
  • Administering IC
    HL
  • Application Type
    3
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    839
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZHL1
  • Study Section Name
  • Organization Name
    CHILDREN'S HOSPITAL OF ORANGE COUNTY
  • Organization Department
  • Organization DUNS
  • Organization City
    ORANGE
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    928683874
  • Organization District
    UNITED STATES